HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure

Sebastiaan J van Hal*, Belinda Herring1, Zaquan Deris1,3, Bin Wang2, Nitin K Saksena2 and Dominic E Dwyer1

Address: 1Centre for Infectious Diseases and Microbiology, ICPMR Westmead Hospital, University of Sydney, Westmead 2145, NSW, Australia, 2Retroviral Genetics Division, Centre for Virus Research, Westmead Millennium Institute, Westmead 2145, NSW, Australia and 3Universiti Sains Malaysia, Department of Medical Microbiology and Parasitology, Kota Bharu, Kelantan, Malaysia

Email: Sebastiaan J van Hal* - vanhal@gotalk.net.au; Belinda Herring - b.herring@usyd.edu.au; Zaquan Deris - zderis@swahs.health.nsw.gov.au; Bin Wang - bin_wang@wmi.usyd.edu.au; Nitin K Saksena - nitin_saksena@wmi.usyd.edu.au; Dominic E Dwyer - dominic.dwyer@swahs.health.nsw.gov.au

* Corresponding author

Abstract

In a recent summary of integrase sequences, primary integrase inhibitor mutations were rare. In a review of integrase inhibitor-naïve Australian HIV-1 sequences, primary mutations were not identified, although the accessory mutation G140S was detected. A link with previous antiretroviral therapy, intra-subtype B divergence across the integrase gene and transmission of integrase polymorphisms were also noted. Based on these findings, we would recommend ongoing surveillance of integrase mutations, and integrase region sequencing for patients prior to commencement of integrase inhibitors.

Correspondence

We congratulate Rhee and colleagues for their extensive review of the natural variation of HIV-1 integrase in 1500 integrase sequences from B and non-B HIV-1 subtypes [1]. This study provides significant insights into integrase inhibitor (INIs) resistance mutations and polymorphisms, and forms an essential component in guiding therapeutic decisions. This has become even more imperative since the licensing of antiretroviral therapy, intra-subtype B divergence across the integrase gene and transmission of integrase polymorphisms were also noted. Based on these findings, we would recommend ongoing surveillance of integrase mutations, and integrase region sequencing for patients prior to commencement of integrase inhibitors.

Published: 9 February 2009
Retrovirology 2009, 6:12 doi:10.1186/1742-4690-6-12

This article is available from: http://www.retrovirology.com/content/6/1/12

© 2009 van Hal et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
isolated single accessory mutations (i.e. T97A, V151I, G163R, I203M and S230N) remains unknown. In contrast, isolated L74A/I/M has no effect on in vitro resistance while G140S is associated with an in vitro 5–10 fold decrease in susceptibility [4] (Personal communication with Merck Sharp & Dohme). This mutation is not only responsible for partial RAL resistance but also restores viral fitness when combined with the Q148R/H mutation [5]. G140S was not documented by Rhee et al. in their review [1]. However, in a small study conducted at Westmead Hospital, Sydney, Australia, G140S was detected in 2 INI-naïve patients, as were the other accessory mutations: L74I/M (n = 8), T97A (n = 2), V151I (n = 3) and I203M (n = 4). In this study, plasma from 133 INI-naïve patients were sequenced (GenBank Accession Numbers FJ554674–FJ554806) across integrase. Most sequences belonged to HIV-1 subtype B (n = 109). The remaining 25 sequences include subtype A (n = 4); subtype C (n = 8); subtype G (n = 4), CRF02_AG (n = 3), CRF01_AE (n = 2) and CRF33_01B (n = 3). Using the same HIV-1 subtype B consensus sequence as Rhee and colleagues, similar subtype-specific consensus residues were detected. For the newly described CRF33_01B subtype (not studied by Rhee et al.) several polymorphisms were detected in all sequences i.e. V31I, T112V, T125A [6]. Although other residues were similar to other non-B subtypes (varying from the consensus B subtype), no firm conclusions can be made because the number of CRF33_01B sequences studied was small.

The influence of prior ARV therapy (not including INIs) was not addressed by Rhee et al. Interestingly, we found that previous ARV therapy was associated with greater IN divergence (the mean intra-subtype B divergence was 5.1% +/- 0.17 in 59 samples from treatment-experienced patients compared to a mean of 3.8% +/- 0.18 in 50 treatment-naive samples; p < 0.01). This finding suggests that ARV-induced changes in other parts of the HIV-1 genome may be linked to integrase polymorphisms. This is supported by data that has detected several integrase polymorphisms (e.g. M154I, V165I and M185I) positively associated with specific RT mutations (F227L and T215Y) in samples from treated individuals [7]. We were unable to find any evidence to suggest this co-evolution at the IN and RT sites, probably as a consequence of our small sample size. It still remains unknown whether the efficacy of INIs is affected by previous ARV therapy selection pressure. However, both G140S mutations in our study occurred in samples from previously ARV-treated individuals, suggesting that previous therapy may result in reduced INI efficacy, and further supporting IN sequencing in patients contemplating INI therapy initiation.

A further question not addressed by Rhee and colleagues was the potential transmission of IN polymorphisms. In our study, three subtype B-infected patients (GenBank Accession Numbers FJ554692; FJ554718; FJ554739) were known to have acquired their infection from the same source. These samples all had IN sequencing performed on plasma, cultured isolates and peripheral blood mononuclear cells. Several IN polymorphisms (S24N, D25E, T112I, S119P, T125A, K136Q, V201I, L234I and S283G) were present in all three patients, suggesting that they were readily transmitted. Interestingly, the sequences did not vary by more than 0.2%, suggesting little sequence variation between the various HIV-1 "compartments".

In conclusion, ongoing surveillance of integrase inhibitor polymorphisms is important, including in non-subtype B viruses. We suggest that IN sequencing should be undertaken in all patients prior to INI commencement to enable further elucidation of resistance pathways, and determination of the significance of subtype-specific polymorphisms in both ARV-naive and experienced individuals.

Consent and ethics approval HREC 2008/3/4.10 (2750)

Patient consent was deemed unnecessary by the local Ethics committee for several reasons: Antiviral resistance testing is the standard of care for all Australian HIV infected patients. Stored samples used for previous antiviral resistance testing were available therefore no patients were approached for this study to provide new blood samples. Furthermore, it was felt that this testing could potentially benefit the patient in future when integrase inhibitors may be required in the treatment regimen.

Competing interests

D. Dwyer is a member of the advisory boards for Merck Sharp & Dohme Australia and other local pharmaceutical companies. Dr S. van Hal has received sponsorship to attend a local HIV conference from Merck Sharp & Dohme Australia

Authors’ contributions

DED, NKS conceived the study. SJvH, BH, BW and DZ performed the sequences and subsequent analysis. SJvH wrote the paper. All authors have read and approved the final manuscript.

Acknowledgements

Funding for this project was provided by an educational grant from Merck Sharp & Dohme, Australia

References

1. Rhee SY, Liu TF, Kiuchi M, Zioni R, Gifford RJ, Holmes SP, Shafer RW: Natural variation of HIV-1 group M integrase: implications for a new class of antiretroviral inhibitors. Retrovirology 2008, 5:74.
2. Cooper DA, Steigbigel RT, Gazzoli JM, Rockstroh JK, Katlama C, Yani P, Lazzarin A, Cement B, Kumar PN, Eron JE, Schechter M, Markowitz M, Lourfy MR, Lennox J, Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ,
Nessly ML, DiNubile MJ, Isaacs RD, Tepler H, Nguyen BY, BENCH-MRK Study Teams: Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008, 359:355-65.

3. Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Ciotet B, Zhao J, Chen J, Ryan DM, Rhodes RR, Kilgar JA, Glode LR, Strohmaier KM, Mebohn AR, Miller MD, Hazuda DJ, Nessly ML, DiNubile MJ, Isaacs RD, Nguyen BY, Tepler H, BENCH-MRK Study Teams: Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008, 359:339-54.

4. Myers RE, Pillay D: Analysis of natural sequence variation and covariation in human immunodeficiency virus type 1 integrase. J Virol 2008, 82:9228-35.

5. Delelis O, Malet I, Na L, Tchertanov L, Calvez V, Marcelin AG, Subra F, Deprez E, Mouscadet JF: The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res 2009 in press.

6. Wang B, Lau KA, Ong LY, Shah M, Steain MC, Foley B, Dwyer DE, Chew CB, Kamarulzaman A, Ng KP, Saksera NK: Complex patterns of the HIV-1 epidemic in Kuala Lumpur, Malaysia: evidence for expansion of circulating recombinant form CRF33_01B and detection of multiple other recombinants. Virology 2007, 367:288-97.

7. Ceccherini-Silberstein F, Malet I, Fabeni L, Sivicher V, Gori C, Dimonte S, et al.: Specific mutations related to resistance to HIV-1 integrase inhibitors are associated with reverse transcriptase mutations in HAART-treated patients. Antivir Ther 2007.